ACRO Biomedical Reports Continued Revenue Decline and Increased Net Loss in Q1 2026

ACRO Biomedical Co., Ltd. reported its financial results for the first quarter of 2026, revealing a continued lack of revenue and a net loss of $43,774, compared to a net loss of $10,301 for the same period in 2025. The company has not generated any revenue since December 31, 2022, and its operating expenses increased significantly to $60,271 from $8,934 year-over-year. The increase in expenses is primarily attributed to professional fees related to its status as a public company. The company’s cash position also declined, with total current assets dropping to $3,873 from $14,098 at the end of 2025.

In terms of liabilities, ACRO Biomedical's total current liabilities rose to $431,108 from $401,062, leading to a stockholders' deficit of $427,235 as of March 31, 2026. The company continues to rely heavily on advances from a minority stockholder, which accounted for $49,596 in financing activities during the quarter. This reliance raises concerns about the company's ability to sustain operations without generating revenue or securing additional funding.

Operationally, ACRO Biomedical has faced significant challenges, including the impact of COVID-19 restrictions in China, which have affected its customer base and sales potential. The company has not made any sales since 2018 and has not developed any new products from its research and development efforts, which concluded in 2023. The absence of a trading market for its common stock further complicates its financial situation, as it limits the company's ability to raise capital.

Looking ahead, the company acknowledges substantial doubt about its ability to continue as a going concern. Management has indicated that without generating revenue or securing additional funding, the company may not be able to sustain its operations. The financial statements reflect this uncertainty, as they do not include adjustments that might be necessary if the company cannot continue as a going concern. The company is exploring potential avenues for funding but has no agreements in place at this time.

Overall, ACRO Biomedical's financial performance in the first quarter of 2026 highlights ongoing operational difficulties and a critical need for strategic changes to improve its financial health and market position. The company’s future remains uncertain as it navigates these challenges while seeking to develop its business and generate revenue.